Accumulating evidence indicates that the PD-L1/PD-1 pathway is aberrantly activated in various pain models. And blocking PD-L1/PD-1 pathway will aggravate pain behaviors. This review aims to summarize the emerging evidence on the role of the PD-L1/PD-1 pathway in alleviating pain and provide...
The PD-1 costimulatory receptor negatively regulates T cell receptor signaling upon interacting with its ligands PDL1 and PDL2 expressed on antigen presenting cells (APCs) and has a key role in maintaining self-tolerance. In the present study we examined the role of PD-1 in Histoplasma capsula...
We also discuss limitations associated with anti-PD-1 therapy. The blockade of the PD-1-PD-L1 pathway has shown promising results in clinical trials and has revolutionized melanoma immunotherapy. 展开 关键词: Nivolumab MK-3475 Ipilimumab PD-1 PD-L1 Programmed cell death receptor 1 Immunotherapy ...
The most important limitation of our review is that the most of the data of anti-PD-1/PD-L1 therapies in GI cancers reliance on to phase I and II trials. Currently, there are two anti-PD-1 and three anti-PD-L1 agents that approved by FDA. After the treatment efficacy of immune ...
Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis putatively served as a mechanism for tumor evasion of host tumor antigen...
Over the past decade, several immunotherapies have been approved for the treatment of melanoma. The most prominent of these are the immune checkpoint inhibitors, which are antibodies that block the inhibitory effects on the immune system by checkpoint receptors, such as CTLA-4, PD-1 and PD-L1....
The unsatisfactory response rate of immune checkpoint blockade (ICB) immunotherapy severely limits its clinical application as a tumor therapy. Here, we generate a vaccine-based nanosystem by integrating siRNA for Cd274 into the commercial human papillom
The programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) pathway mainly attracted attention in immuno-oncology, leading to the development of immune checkpoint therapy. It has, however, much broader importance for tissue physiology and
Dr. Honjo was the first to clone PD-1, in 1992 [4], and he described PD-1 as another important immune checkpoint of T cells [5]. Subsequently, his work led to identifying its ligands as B7-H1 [6] or PD-L1 [7]. Subsequent extensive studies on the PD-1/PD-L1 pathway led to ...
After the crystal structure of mouse CLDN-15 revealed the first snapshot of a CLDN monomer at atomic resolution [27], a new model based on the crystallographic arrangement of CLDN-15 and the results of cysteine cross-linking experiments was established from mutants of CLDN-15 and CLDN-2 ...